Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.34
CTIX's Cash to Debt is ranked higher than
65% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. CTIX: 5.34 )
CTIX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 5.34

F-Score: 3
Z-Score: 20.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -284.27
CTIX's ROE (%) is ranked lower than
51% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. CTIX: -284.27 )
CTIX' s 10-Year ROE (%) Range
Min: -235   Max: -235
Current: -284.27

ROA (%) -102.01
CTIX's ROA (%) is ranked higher than
52% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. CTIX: -102.01 )
CTIX' s 10-Year ROA (%) Range
Min: -2870.38   Max: -119.33
Current: -102.01

-2870.38
-119.33
ROC (Joel Greenblatt) (%) -31713.94
CTIX's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. CTIX: -31713.94 )
CTIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -41220.51   Max: -41220.51
Current: -31713.94

EBITDA Growth (3Y)(%) 5.30
CTIX's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CTIX: 5.30 )
CTIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 81.7
Current: 5.3

0
81.7
EPS Growth (3Y)(%) 12.60
CTIX's EPS Growth (3Y)(%) is ranked higher than
85% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. CTIX: 12.60 )
CTIX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 100
Current: 12.6

0
100
» CTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 32.60
CTIX's P/B is ranked lower than
54% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. CTIX: 32.60 )
CTIX' s 10-Year P/B Range
Min: 0   Max: 338.2
Current: 32.6

0
338.2
EV-to-EBIT -26.44
CTIX's EV-to-EBIT is ranked lower than
53% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CTIX: -26.44 )
CTIX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -26.44

Current Ratio 1.56
CTIX's Current Ratio is ranked higher than
56% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. CTIX: 1.56 )
CTIX' s 10-Year Current Ratio Range
Min: 0.01   Max: 2.4
Current: 1.56

0.01
2.4
Quick Ratio 1.56
CTIX's Quick Ratio is ranked higher than
59% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CTIX: 1.56 )
CTIX' s 10-Year Quick Ratio Range
Min: 0.01   Max: 2.4
Current: 1.56

0.01
2.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 87.00
CTIX's Price/Net Cash is ranked higher than
61% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. CTIX: 87.00 )
CTIX' s 10-Year Price/Net Cash Range
Min: 105.33   Max: 219.5
Current: 87

105.33
219.5
Price/Net Current Asset Value 87.00
CTIX's Price/Net Current Asset Value is ranked higher than
57% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. CTIX: 87.00 )
CTIX' s 10-Year Price/Net Current Asset Value Range
Min: 79   Max: 219.5
Current: 87

79
219.5
Price/Tangible Book 65.30
CTIX's Price/Tangible Book is ranked lower than
58% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. CTIX: 65.30 )
CTIX' s 10-Year Price/Tangible Book Range
Min: 219.5   Max: 219.5
Current: 65.3

Earnings Yield (Greenblatt) -3.80
CTIX's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. CTIX: -3.80 )
CTIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.5   Max: 0
Current: -3.8

-4.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cellceutix Corporation, formerly known as EconoShare was incorporated on August 1, 2005 in the State of Nevada and was organized for the purpose of developing a B2B website for an Asset Sharing market place and transaction system. On December 6, 2007, EconoShare, Inc. acquired Cellceutix Pharma, Inc., a privately owned Delaware corporation with Cellceutix Pharma becoming a wholly-owned subsidiary of EconoShare, Inc. As a result of the Exchange with Cellceutix Pharma, Inc., the Company has adopted the business plan of Cellceutix Pharma, Inc. and now is into an early stage developmental biopharmaceutical Company. It has acquired rights to seven (7) different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or might exist in the future. The Company would initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin(tm), for the treatment of certain cancers. This compound is furthest along in in-vivo studies in small animals. Based on the results, the Company has decided to advance Kevetrin along the regulatory and clinical pathway. The Company's current portfolio of product candidates in pre-clinical development includes: (i) two (2) anti-cancer agents targeting multiple tumors; (ii) one (1) candidate targeting psoriasis; (iii) one (1) candidate targeting rheumatoid arthritis; (iv) one (1) candidate with potential for indications of osteo-arthritis/asthma; (v) one (1) candidate with a potential for indications of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson's Disease; and (vi) a small molecule with potential for development to treat hypertensive emergency. Its product candidate, Kevetrin. Kevetrin is initially being developed to treat certain cancers. The Company is in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of cancer and inflammatory disease. The Company's compounds are still in preclinical development. It competes with biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to its operations. In the United States, drugs are subject to rigorous regulation by the United States Food and Drug Administration ('FDA'). The Federal Food, Drug and Cosmetic Act, and other federal and state statutes and regulations, govern the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of its products.
» More Articles for CTIX

Headlines

Articles On GuruFocus.com
Cellceutix Enthusiastic About Proposed Budget Increase to $1.2 Billion to Fight Drug-Resistance Bact Jan 27 2015 
Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis Jan 26 2015 
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Cong Jan 22 2015 
Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in C Jan 20 2015 
Cellceutix Invites All to Attend Company's Live Webcast of Presentation at Biotech Showcase 2015 Tod Jan 12 2015 
Cellceutix Releases Confidence Interval Statistics Showing Clinical Success Rates for Brilacidin in Jan 05 2015 
Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer Dec 29 2014 
Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in P Dec 22 2014 
Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin Dec 10 2014 
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA Dec 08 2014 

More From Other Websites
IRB Approves Additional Enrollment in Cellceutix's Clinical Trial of New Cancer Drug Candidate for... May 22 2015
CELLCEUTIX CORP Financials May 19 2015
10-Q for Cellceutix Corp. May 14 2015
Does Your Portfolio Have A Healthy Dose of HealthCare Stocks? May 14 2015
Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies... May 13 2015
CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report May 11 2015
CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Apr 27 2015
Cellceutix Selects Independent Directors and Committee Members Apr 27 2015
Cellceutix Provides Corporate Update Apr 21 2015
Cellceutix PIND Meeting Scheduled With FDA for Hidradenitis Suppurativa Apr 13 2015
Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement Apr 01 2015
CELLCEUTIX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Mar 31 2015
Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events... Mar 24 2015
Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and... Mar 16 2015
Cellceutix to Expand Its Skin Product Pipeline Mar 02 2015
CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report Feb 09 2015
Cellceutix Enthusiastic About Proposed Budget Increase to $1.2 Billion to Fight Drug-Resistance... Jan 27 2015
Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis Jan 26 2015
Will Cannabis Be The Biggest Thing In Biotech For 2015? Jan 22 2015
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European... Jan 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK